PMID- 25626602
OWN - NLM
STAT- MEDLINE
DCOM- 20150928
LR  - 20181113
IS  - 1399-0039 (Electronic)
IS  - 0001-2815 (Print)
IS  - 0001-2815 (Linking)
VI  - 85
IP  - 2
DP  - 2015 Feb
TI  - HLA class II diversity in HIV-1 uninfected individuals from the placebo arm of 
      the RV144 Thai vaccine efficacy trial.
PG  - 117-26
LID - 10.1111/tan.12507 [doi]
AB  - The RV144 HIV vaccine trial in Thailand elicited antibody responses to the 
      envelope of HIV-1, which correlated significantly with the risk of HIV-1 
      acquisition. Human leukocyte antigen (HLA) class II molecules are essential in 
      antigen presentation to CD4 T cells for activation of B cells to produce 
      antibodies. We genotyped the classical HLA-DRB1, DQB1, and DPB1 genes in 450 
      individuals from the placebo arm of the RV144 study to determine the background 
      allele and haplotype frequencies of these genes in this cohort. High-resolution 4 
      and 6-digit class II HLA typing data was generated using sequencing-based 
      methods. The observed diversity for the HLA loci was 33 HLA-DRB1, 15 HLA-DQB1, 
      and 26 HLA-DPB1 alleles. Common alleles with frequencies greater than 10% were 
      DRB1*07:01, DRB1*09:01, DRB1*12:02, DRB1*15:02, DQB1*02:01/02, DQB1*03:01, 
      DQB1*03:03, DQB1*05:01, DQB1*05:02, DPB1*04:01:01, DPB1*05:01:01, and 
      DPB1*13:01:01. We identified 28 rare alleles with frequencies of less than 1% in 
      the Thai individuals. Ambiguity for HLA-DPB1*28:01 in exon 2 was resolved to 
      DPB1*296:01 by next-generation sequencing of all exons. Multi-locus haplotypes 
      including HLA class I and II loci were reported in this study. This is the first 
      comprehensive report of allele and haplotype frequencies of all three HLA class 
      II genes from a Thai population. A high-resolution genotyping method such as 
      next-generation sequencing avoids missing rare alleles and resolves ambiguous 
      calls. The HLA class II genotyping data generated in this study will be 
      beneficial not only for future disease association/vaccine efficacy studies 
      related to the RV144 study, but also for similar studies in other diseases in the 
      Thai population, as well as population genetics and transplantation studies.
CI  - (c) 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Baldwin, K M
AU  - Baldwin KM
AD  - U.S. Military HIV Research Program, Walter Reed Army Institute of Research, 
      Silver Spring, MD, USA; Henry M. Jackson Foundation for the Advancement of 
      Military Medicine, Bethesda, MD, USA.
FAU - Ehrenberg, P K
AU  - Ehrenberg PK
FAU - Geretz, A
AU  - Geretz A
FAU - Prentice, H A
AU  - Prentice HA
FAU - Nitayaphan, S
AU  - Nitayaphan S
FAU - Rerks-Ngarm, S
AU  - Rerks-Ngarm S
FAU - Kaewkungwal, J
AU  - Kaewkungwal J
FAU - Pitisuttithum, P
AU  - Pitisuttithum P
FAU - O'Connell, R J
AU  - O'Connell RJ
FAU - Kim, J H
AU  - Kim JH
FAU - Thomas, R
AU  - Thomas R
LA  - eng
GR  - Y01 I12047001/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (AIDS Vaccines)
RN  - 0 (HLA-DP beta-Chains)
RN  - 0 (HLA-DPB1 antigen)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Placebos)
SB  - IM
MH  - AIDS Vaccines/*immunology
MH  - Alleles
MH  - Gene Frequency
MH  - *Genetic Variation
MH  - HIV Infections/*genetics/*immunology
MH  - HIV-1/*immunology
MH  - HLA-DP beta-Chains/genetics
MH  - HLA-DQ beta-Chains/genetics
MH  - HLA-DRB1 Chains/genetics
MH  - Haplotypes/genetics
MH  - Histocompatibility Antigens Class II/*genetics
MH  - Humans
MH  - Placebos
MH  - Thailand
MH  - Treatment Outcome
PMC - PMC4552183
MID - NIHMS657688
OTO - NOTNLM
OT  - HIV-1
OT  - HLA-DPB1
OT  - HLA-DQB1
OT  - HLA-DRB1
OT  - Human leukocyte antigen
OT  - RV144
COIS- The authors confirm that there are no conflicts of interest.
EDAT- 2015/01/30 06:00
MHDA- 2015/09/29 06:00
PMCR- 2016/02/01
CRDT- 2015/01/29 06:00
PHST- 2014/06/09 00:00 [received]
PHST- 2014/11/11 00:00 [revised]
PHST- 2014/12/13 00:00 [accepted]
PHST- 2015/01/29 06:00 [entrez]
PHST- 2015/01/30 06:00 [pubmed]
PHST- 2015/09/29 06:00 [medline]
PHST- 2016/02/01 00:00 [pmc-release]
AID - 10.1111/tan.12507 [doi]
PST - ppublish
SO  - Tissue Antigens. 2015 Feb;85(2):117-26. doi: 10.1111/tan.12507.